A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sol Gel Technologies Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,500 shares of SLGL stock, worth $660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,500
Previous 5,400 72.22%
Holding current value
$660
Previous $4,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.37 - $0.96 $10,528 - $27,316
28,455 Added 254.65%
39,629 $26,000
Q2 2024

Aug 14, 2024

SELL
$0.66 - $1.05 $15 - $24
-23 Reduced 0.21%
11,174 $9,000
Q1 2024

May 15, 2024

SELL
$0.95 - $1.5 $5,758 - $9,093
-6,062 Reduced 35.12%
11,197 $10,000
Q4 2023

Feb 14, 2024

BUY
$0.92 - $1.6 $3,510 - $6,105
3,816 Added 28.39%
17,259 $18,000
Q3 2023

Nov 14, 2023

SELL
$1.63 - $3.94 $7,026 - $16,985
-4,311 Reduced 24.28%
13,443 $21,000
Q2 2023

Aug 14, 2023

BUY
$2.99 - $4.15 $53,084 - $73,679
17,754 New
17,754 $53,000

Others Institutions Holding SLGL

About Sol-Gel Technologies Ltd.


  • Ticker SLGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,129,500
  • Market Cap $10.2M
  • Description
  • Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has compl...
More about SLGL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.